

Edited by
Horst Bluethmann
Pamela Ohashi

A microscopic image of cells, likely showing various organelles and structures, serving as a background for the title text.

Transgenesis and Targeted Mutagenesis in Immunology



Transgenesis and Targeted Mutagenesis in Immunology

This page intentionally left blank

Transgenesis and Targeted Mutagenesis in Immunology

Edited by

Horst Bluethmann

*Department of Biology
Pharmaceutical Research
New Technologies
F. Hoffmann-LaRoche Ltd.
Basel, Switzerland*

Pamela S. Ohashi

*Ontario Cancer Institute
Department of Medical Biophysics
University of Toronto
Toronto, Ontario, Canada*



Academic Press

A Division of Harcourt Brace & Company

San Diego New York Boston London Sydney Tokyo Toronto

Background: Morphology of bone marrow cells
from membrane-lysozyme double-transgenic mice.

This book is printed on acid-free paper. (∞)

Copyright © 1994 by ACADEMIC PRESS, INC.

All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Academic Press, Inc.

A Division of Harcourt Brace & Company

525 B Street, Suite 1900, San Diego, California 92101-4495

United Kingdom Edition published by

Academic Press Limited

24-28 Oval Road, London NW1 7DX

Library of Congress Cataloging-in-Publication Data

Transgenesis and targeted mutagenesis in immunology /

edited by Horst Bluethmann, Pamela S. Ohashi

p. cm.

Includes bibliographical references and index.

ISBN 0-12-105760-7

1. Transgenic mice. 2. Mice--Immunology. 3. Immunology--Animal models. I. Bluethmann, Horst. II. Ohashi, Pamela S.

[DNLM: 1. Mutagenesis Site-Directed. 2. Mice, Transgenic--immunology. 3. Disease Models, Animal. 4. Immune System. QW 541 1772 1994]

QR182.2.A54T73

619'.93--dc20 DNLM/DLC

for Library of Congress

93-43197

CIP

PRINTED IN THE UNITED STATES OF AMERICA

94 95 96 97 98 99 BB 9 8 7 6 5 4 3 2 1

Contents

Contributors xiii

Preface xix

1

Transgenic Mouse Models to Study VDJ Recombination

Françoise Watrin, Corinne Femex, Myriam Capone, Branka Horvat, Danielle Caillol, and Pierre Ferrier

- I. Introduction 1
- II. Transgenic Model to Define VDJ Recombination
Regulatory Elements: Evidence That
Recombinational Sequences Are Associated with
Lymphoid Transcriptional Enhancers 3
- III. Other Transgenic Models 8
- IV. Future Prospects 10
- V. Concluding Remarks 12
- References 12

2

Lymphocyte Development and Function in T Cell Receptor and RAG-1 Mutant Mice

Peter Mombaerts and Susumu Tonegawa

- I. Introduction 15
- II. Creation of Mutant Mice 16
- III. Thymocyte Development 17
- IV. Model for the Role of TCR Genes in $\alpha\beta$ Thymocyte
Differentiation 28
- V. Lymphocyte Function 29
- References 34

3**RAG-2-Deficient Blastocyst Complementation****Jianzhu Chen and Frederick W. Alt**

- I. Introduction 35
- II. Procedures 36
- III. Applications 43
- IV. Prospects 46
- References 48

4**Role of CD4 and CD8 in Determining Cell Fate in the Thymus****Craig B. Davis and Ellen A. Robey**

- I. Background 51
- II. Coreceptor Transgenes and TCR Repertoire Selection 53
- III. Coreceptor Transgenes and Thymocyte Lineage Commitment 57
- IV. Other Data Pertaining to Coreceptor Lineage Commitment 61
- V. Future Directions 63
- References 64

5**T Cell Development in CD4, CD8, and p56^{lck} Gene-Targeted Mice****Valerie A. Wallace, Josef Penninger, and Tak W. Mak**

- I. Introduction 67
- II. T Cell Development in CD4, CD8, and CD4 and CD8 Double-Negative Mice 70
- III. Thymic Development in p56^{lck}-Deficient Mice 78
- IV. Concluding Remarks 79
- References 80

6**T Cell Tolerance in T Cell Receptor Transgenic *lpr/lpr* Mice****John D. Mountz, Tong Zhou, and Horst Bluethmann**

- I. Introduction 84
- II. Effect of T Cell Receptor Transgenes on T Cell Development in *lpr/lpr* Mice 84

- III. Loss of T Cell Tolerance in D^b/HY T Cell Receptor Transgenic *lpr/lpr* Mice 95
- IV. Loss of T Cell Tolerance in V β 8 T Cell Receptor Transgenic MRL *lpr/lpr* Mice Neonatally Tolerized with Staphylococcal Enterotoxin B 99
- V. Costimulatory Signaling in V β 8 T Cell Receptor Transgenic MRL *lpr/lpr* Mice Neonatally Tolerized with Staphylococcal Enterotoxin B 106
- VI. Summary 108
References 109

7**Thymocyte Selection and Peripheral Tolerance Using the Lymphocytic Choriomeningitis Virus as a Model Antigen**

Pamela S. Ohashi, Hans Hengartner, Manuel Battegay, Rolf M. Zinkernagel, and Hanspeter Pircher

- I. Introduction 114
- II. Positive Selection 114
- III. Negative Selection 118
- IV. Tolerance to Peripheral Self-Antigens 121
- V. Factors That Influence the Induction of Self-Reactivity 126
- VI. Prevention of Autoimmune Disease 128
- VII. Concluding Remarks 130
References 130

8**Peripheral T Cell Tolerance: Distinct Levels and Multistep Mechanisms**

Bernd Arnold, Günther Schönrich, Iris Ferber, Judith Alferink, and Günter J. Hämmerling

- I. Introduction 135
- II. Thymic Tolerance Induction by Minute Amounts of Antigen 136
- III. Parameters Controlling Peripheral Tolerance Induction 137
- IV. Distinct Manifestations of Peripheral Tolerance Due to Differential Expression of Self-Antigen 138
- V. Influence of the Amount of Antigen Expressed on Peripheral Tolerance Induction 140

VI. Tolerance Induction as a Multistep Process	144
VII. Anergy versus Memory	146
VIII. Summary and Conclusions	146
References	147

9

Peripheral Tolerance and CD4⁺ T Cells**Bernadette Scott and David Lo**

I. Introduction	149
II. Class II MHC Transgenic Animals	150
III. INS-HA Transgenic Animals	150
IV. TCR INS-HA Transgenic Animals	151
V. Discussion	152
VI. Conclusions	153
References	154

10

Studies of Tolerance, Inflammation, and Autoimmunity in Transgenic Mice**Scott Antonia, Eileen A. Elliott, Sylvie Guerder,
Dominic E. Picarella, Nancy H. Ruddle,
and Richard A. Flavell**

I. Introduction	156
II. TNF α and TNF β Are Sufficient to Induce an Inflammatory Infiltrate but Cannot Induce Autoimmunity	157
III. Antigen Recognition and Its Consequences in SV-40 T Antigen Transgenic Mice	159
IV. Two-Signal Model of T Cell Activation: Role of T Cell Activation in the Induction of Autoimmunity	167
V. Can Locally Produced Interleukin 2 Bypass Tolerance Mechanisms?: Interleukin 2 Expression in Pancreatic B Cells Leads to Insulinitis and Diabetes	169
VI. Concluding Remarks	171
References	172

11**Immunological Studies Utilizing Cytokine Transgenic Mice****Myung-Shik Lee and Nora Sarvetnick**

- I. Introduction 175
- II. Localized Expression of Interferon γ 176
- III. Expression of Interleukin 10, an Immunoinhibitory Cytokine 178
- IV. Expression of Other Cytokines 179
- V. Expression of Molecules Other Than Cytokines 180
- VI. Conclusion 181
- References 181

12**Effect of MHC Class II Encoding Transgenes on Autoimmunity in Nonobese Diabetic Mice****Anne Cooke, Lorraine A. O'Reilly, Alan G. Baxter, Patricia Ozegbe, Patricia R. Hutchings, Nicole M. Parish, Don G. Healey, and Ruby Quarley-Papafio**

- I. Introduction 183
- II. Effect of Transgenic *Ea* Expression on Insulin-Dependent Diabetes Mellitus 185
- III. Effect of Mutated *Ab* Transgenes on Insulin-Dependent Diabetes Mellitus 187
- IV. Conclusion 189
- References 189

13**Development and Function of the Immune System in Mice with Targeted Disruption of the Interleukin 2 Gene****Anneliese Schimpl, Thomas Hünig, Adelheid Elbe, Ingolf Berberich, Susanne Krämer, Hartmut Merz, Alfred C. Feller, Benjamin Sadlack, Hubert Schorle, and Ivan Horak**

- I. Introduction 191
- II. Generation of Interleukin 2-Deficient Mice 192
- III. Lymphopoiesis and Leukocyte Homeostasis in Young and Adult Mutant Mice 193
- IV. Immune Functions in Young Healthy Animals 195
- V. Development of Disease and Mortality of Adult Interleukin 2-Deficient Mice 198

VI. Inflammatory Bowel Disease in Interleukin 2-Deficient Mice	198
VII. Concluding Remarks	199
References	200

14

**Immune Responses in
Interleukin 4-Deficient Mice**

**Guy G. Brusselle, Graham Le Gros, Georges Köhler,
Nathalie Schultze, Pascale Koebel, Johan C. Kips,
Romain A. Pauwels, and Horst Bluethmann**

I. Introduction	203
II. Generation of Interleukin 4-Deficient Mice by Targeted Mutagenesis	205
III. Effect of Interleukin 4 on B Cell Development and Differentiation	205
IV. Effect of Interleukin 4 on T Cell Development and Differentiation	212
V. Role of Interleukin 4 in Allergy	217
VI. Outlook	222
References	223

15

**Manipulation of Transgene-Encoded
Self-Antigens to Explore Mechanisms of
B Cell Tolerance**

Suzanne B. Hartley and Christopher C. Goodnow

I. Introduction	227
II. Effects of Lysozyme on Self-Reactive B Cells	228
III. B Cell Anergy versus Elimination	233
IV. Physiological and Pathological Implications of B Cell Elimination by Arrested Development	246
References	247

16**Transgenic Mouse Model for Peripheral B Cell Tolerance****Hermann Eibel, Petra Fiedler, and Georges Köhler**

- I. Introduction 251
- II. Anti-CD8 IgM Transgenic Mouse Lines 253
- III. Conclusions 261
- References 264

17**Immunobiology of MHC Class I-Deficient Mice****David H. Raulet**

- I. Introduction 267
- II. Production of β_2m -Deficient Mice 269
- III. Effects of β_2m Deficiency on Cell Surface Expression of Class I Molecules 270
- IV. Defective Lymphocyte Development in Class I-Deficient Mice 272
- V. Effect of Class I Deficiency on Susceptibility to Natural Killer Cells and Development of Natural Killer Activity 277
- VI. Transplantation Studies 279
- VII. Responses of Class I-Deficient Mice to Pathogens 283
- VIII. Summary and Conclusions 291
- References 292

18**MHC Class II Mutant Mice****Michael J. Grusby, Jay S. Markowitz, Terri M. Laufer, Richard Lee, Hugh Auchincloss, Jr., and Laurie H. Glimcher**

- I. Introduction 297
- II. Studies in MHC Class II Mutant Mice 298
- III. MHC-Deficient Mice 303
- IV. Conclusion 305
- References 305

Index 309

This page intentionally left blank

Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

Judith Alferink (135) Tumor Immunology Program, Division of Somatic Genetics, German Cancer Research Center, 69120 Heidelberg, Germany

Frederick W. Alt (35) Howard Hughes Medical Institute at Children's Hospital, Department of Genetics, Harvard Medical School, and Center for Blood Research, Boston, Massachusetts 02115

Scott Antonia (155) Section of Immunobiology, and Department of Medicine (Oncology), Yale University School of Medicine, New Haven, Connecticut 06510

Bernd Arnold (135) Tumor Immunology Program, Division of Somatic Genetics, German Cancer Research Center, 69120 Heidelberg, Germany

Hugh Auchincloss, Jr. (297) Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114

Manuel Battegay (113) Institute of Experimental Immunology, University Hospital, 8091 Zürich, Switzerland

Alan G. Baxter (183) Immunology Division, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, England

Ingolf Berberich (191) Institute of Virology and Immunobiology, University of Würzburg, 97078 Würzburg, Germany

Horst Bluethmann (83, 203) Department of Biology, Pharmaceutical Research, New Technologies, F. Hoffmann-LaRoche Ltd., CH-4002 Basel, Switzerland

Guy G. Brusselle (203) Department of Respiratory Diseases, University Hospital, B-9000 Gent, Belgium

Danielle Caillol (1) Centre d'Immunologie, INSERM-CNRS de Marseille-Luminy, 13288 Marseille, France

Myriam Capone (1) Centre d'Immunologie, INSERM-CNRS de Marseille-Luminy, 13288 Marseille, France

Jianzhu Chen (35) Howard Hughes Medical Institute at Children's Hospital, Department of Genetics, Harvard Medical School, and Center for Blood Research, Boston, Massachusetts 02115

Anne Cooke (183) Immunology Division, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, England

Craig B. Davis (51) Department of Microbiology and Immunology, University of California at San Francisco, San Francisco, California 94143

Hermann Eibel (251) Clinical Research Unit on Rheumatology, University of Freiburg Medical Center, D-79108 Freiburg, Germany

Adelheid Elbe (191) Department of Dermatology, University of Vienna Medical School, 1235 Vienna, Austria

Eileen A. Elliott (155) Section of Immunobiology, and Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut 06510

Alfred C. Feller (191) Institute of Pathology, Medical University of Lübeck, 23562 Lübeck, Germany

Iris Ferber (135) Tumor Immunology Program, Division of Somatic Genetics, German Cancer Research Center, 69120 Heidelberg, Germany

Corinne Fernex (1) Centre d'Immunologie, INSERM-CNRS de Marseille-Luminy, 13288 Marseille, France

Pierre Ferrier (1) Centre d'Immunologie, INSERM-CNRS de Marseille-Luminy, 13288 Marseille, France

Petra Fiedler (251) Clinical Research Unit on Rheumatology, University of Freiburg Medical Center, D-79108 Freiburg, Germany

Richard A. Flavell (155) Section of Immunobiology, and Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut 06510

Laurie H. Glimcher (297) Department of Cancer Biology, Harvard School of Public Health, and Department of Rheumatology and Immunology, Harvard Medical School, Boston, Massachusetts 02115

Christopher C. Goodnow (227) Howard Hughes Medical Institute, and Department of Microbiology and Immunology, Beckman Center for Molecular and Genetic Medicine, Stanford University Medical Center, Stanford, California 94305

Michael J. Grusby (297) Department of Cancer Biology, Harvard School of Public Health, and Department of Rheumatology and Immunology, Harvard Medical School, Boston, Massachusetts 02115

Sylvie Guerder (155) Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06510

- Günter J. Hämmerling** (135) Tumor Immunology Program, Division of Somatic Genetics, German Cancer Research Center, 69120 Heidelberg, Germany
- Suzanne B. Hartley** (227) Howard Hughes Medical Institute, and Department of Microbiology and Immunology, Beckman Center for Molecular and Genetic Medicine, Stanford University Medical Center, Stanford, California 94305
- Don G. Healey** (183) Immunology Division, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, England
- Hans Hengartner** (113) Institute of Experimental Immunology, University Hospital, 8091 Zürich, Switzerland
- Ivan Horak** (191) Institute of Virology and Immunobiology, University of Würzburg, 97078 Würzburg, Germany
- Branka Horvat** (1) Laboratoire de Biologie Moléculaire et Cellulaire, Ecole Normale Supérieure de Lyon, 69364 Lyon, France
- Thomas Hünig** (191) Institute of Virology and Immunobiology, University of Würzburg, 97078 Würzburg, Germany
- Patricia R. Hutchings** (183) Immunology Division, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, England
- Johan C. Kips** (203) Department of Respiratory Diseases, University Hospital, B-9000 Gent, Belgium
- Pascale Koebel** (203) Department of Biology, Pharmaceutical Research, New Technologies, F. Hoffmann-LaRoche Ltd., CH-4002 Basel, Switzerland
- Georges Köhler** (203, 251) Max-Planck-Institut für Immunobiologie, D-79108 Freiburg, Germany
- Susanne Krämer** (191) Institute of Virology and Immunobiology, University of Würzburg, 97078 Würzburg, Germany
- Terri M. Laufer** (297) Department of Cancer Biology, Harvard School of Public Health, Boston, Massachusetts 02115, and Department of Rheumatology and Immunology, Harvard Medical School, Boston, Massachusetts 02115
- Graham Le Gros** (203) Department IBA, Ciba-Geigy, CH-4002 Basel, Switzerland
- Myung-Shik Lee** (175) Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037
- Richard Lee** (297) Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114
- David Lo** (149) Department of Immunology, The Scripps Research Institute, La Jolla, California 92037

- Tak W. Mak** (67) Amgen Institute, Ontario Cancer Institute, Departments of Immunology and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M4X 1K9
- Jay S. Markowitz** (297) Department of Cancer Biology, Harvard School of Public Health, Boston, Massachusetts 02115, and Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114
- Hartmut Merz** (191) Institute of Pathology, Medical University of Lübeck, 23562 Lübeck, Germany
- Peter Mombaerts** (15) Howard Hughes Medical Institute at the Center for Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
- John D. Mountz** (83) Department of Medicine and the Veterans Administration Medical Center, The University of Alabama at Birmingham, Birmingham, Alabama 35294
- Lorraine A. O'Reilly** (183) Immunology Division, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, England
- Pamela S. Ohashi** (113) Ontario Cancer Institute, Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M4X 1K9
- Patricia Ozegbe** (183) Immunology Division, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, England
- Nicole M. Parish** (183) Immunology Division, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, England
- Romain A. Pauwels** (203) Department of Respiratory Diseases, University Hospital, B-9000 Gent, Belgium
- Josef Penninger** (67) Amgen Institute, Ontario Cancer Institute, Departments of Immunology and Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M4X 1K9
- Dominic E. Picarella** (155) Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06510
- Hanspeter Pircher** (113) Institute of Experimental Immunology, University Hospital, 8091 Zürich, Switzerland
- Ruby Quartey-Papfio** (183) Immunology Division, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, England
- David H. Raulet** (267) Division of Immunology, Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, California 94720
- Ellen A. Robey** (51) Division of Immunology, Department of Cell and Molecular Biology, University of California at Berkeley, Berkeley, California 94720
- Nancy H. Ruddle** (155) Department of Epidemiology and Public Health, and